Clinical trials: 2019-nCoV Pneumonia
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
Covid19
Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)
Kit for reading vital signs (thermometer, wrist blood pressure device, finger oximeter) and with study drug is overnighted to qualified subjects with early symptoms of COVID-19.
- Trial name
- Pepcid4COV19 (NCT04565392)
- Testing
- Famotidine 20 milligram tablet
- Where
- United States
- Sponsor
- drpykessupplements.com
Covid19, Sepsis
Blood Markers for Identifying & Investigating Infection With COVID19 & Sepsis in Children.
Corona Virus Disease or COVID-19 is caused by SARS-CoV-2 virus. There have been reports of serious COVID-19 illness in children. In addition it has been linked to clusters of children presenting with high fevers and inflammation.
- Trial name
- pSeP (NCT04904523)
- Testing
- Diagnostic Test:Blood test
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Cardiff University
COVID-19
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads…
- Trial name
- NCT04681079
- Testing
- albuterol sulfate (MDI), albuterol sulfate (nebulizer)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Theravance Biopharma
Covid19
COVID-19 Soliris Expanded Access Protocol
This protocol provides participants with COVID-19 access to Soliris.
- Trial name
- NCT04802083
- Testing
- Eculizumab
- Sponsor
- Alexion Pharmaceuticals, Inc.
Covid19
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability…
- Trial name
- COMET-PEAK (NCT04779879)
- Testing
- Sotrovimab (Gen1), Sotrovimab (Gen2)
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 354 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19
COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19
The primary objectives of the study are: To characterize the concentrations of casirivimab+imdevimab in serum over time To evaluate the safety and tolerability of casirivimab+imdevimab The secondary objective of the study is: To…
- Trial name
- NCT05092581
- Testing
- casirivimab+imdevimab
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy, Chronic Stable Illness
Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19
The primary objectives are: To assess the occurrence of adverse events of special interest (AESIs) in participants treated with repeated subcutaneous (SC) doses of REGN10933+REGN10987 compared to placebo To assess the…
- Trial name
- NCT04519437
- Testing
- REGN10933+REGN10987
- Where
- 7 sites in United States
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Coronavirus Disease 2019 (COVID-19), Post-Exposure Prophylaxis
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers
Background: The rapid spread and high infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) makes identifying an effective prophylaxis agent highly important.
- Trial name
- NCT04438837
- Testing
- Hydroxychloroquine
- Where
- Israel
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
COVID-19
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection
The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo.
- Trial name
- NCT04666441
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 57 sites in United States
- Volunteers
- 1,149 people
- Sponsor
- Regeneron Pharmaceuticals
2019-nCoV Pneumonia
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia
Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients.
- Trial name
- NCT04261270
- Testing
- ASC09F+Oseltamivir, Ritonavir+Oseltamivir, Oseltamivir
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tongji Hospital
Post-COVID Condition, Long COVID
Long-Term Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Undergoing Preoperative Anesthesia Evaluation
The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in persistent health problems in a significant proportion of individuals after recovery from the acute infection.
- Conditions
- Post-COVID Condition, Long COVID, Sequelae of COVID-19
- Trial name
- NCT07435805
- Testing
- Post-COVID Clinical Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 400 people
- Sponsor
- Elazıg Fethi Sekin Sehir Hastanesi
Sars-CoV2, Covid19
Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry
Patients presenting with the coronavirus-2019 disease (COVID-19) have a very high risk of cardiovascular adverse events, including death from cardiovascular causes.
- Conditions
- Sars-CoV2, Covid19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- CV-COVID-19 (NCT04359927)
- Where
- Spain
- Volunteers
- 4,538 people
- Sponsor
- Hospital Clinic of Barcelona
Covid19, Coronavirus Disease 2019
SOLIDARITY Finland Plus Long-COVID
The SOLIDARITY PLUS Finland Long-COVID trial aims to assess the long-term effects of imatinib and infliximab, used during acute hospitalization due to COVID-19-infection, on long-COVID symptoms and quality of life (QoL) using…
- Conditions
- Covid19, Coronavirus Disease 2019, SARS-CoV-2 Acute Respiratory Disease
- Trial name
- NCT05220280
- Testing
- Imatinib, Infliximab
- Where
- Finland
- Volunteers
- 400 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
COVID-19
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.
- Trial name
- NCT04452474
- Testing
- Olokizumab 64 mg
- Sponsor
- R-Pharm
COVID-19
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in…
- Trial name
- NCT04542694
- Testing
- Favipiravir, Standard of care
- Where
- 5 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Promomed, LLC
Coronavirus Disease 2019 (COVID-19)
Collection of Anti-SARS-CoV-2 Immune Plasma
Background: The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 is a mild to moderate respiratory illness. But it can also be more severe and even lead to death.
- Trial name
- NIAID (NCT04344977)
- Where
- 3 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID-19 and Anti-CD14 Treatment Trial
This study aims to address the following objectives: 1. To determine the efficacy of IC14, an anti-CD14 chimeric monoclonal antibody, in patients hospitalized with respiratory disease and hypoxemia due to SARS-CoV-2, in terms of…
- Trial name
- CaTT (NCT04391309)
- Testing
- anti-CD14, remdesivir
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Hydrogen-oxygen Gas
Hydrogen-Oxygen Generator With Nebulizer for Adjuvant Treatment of COVID-19 Positive Patients
This is a prospective, multicenter, randomized, controlled, superiority clinical trial. It is expected that the test group would have better effectiveness than the control group in the primary evaluation indicator (time to…
- Conditions
- Covid19, Hydrogen-oxygen Gas, AMS-H-03
- Trial name
- NCT05539664
- Testing
- Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Ruijin Hospital